

Rev: A

Release Date: 04/18/2014

IVI

## PAX5 (EP156)

Clone	EP156
Source	Rabbit Monoclonal
Cat #	PR064-6ml RTU PR064-3ml RTU CR064-0.1ml Conc CR064-0.5ml Conc
Regulatory Status	IVD

## Intended Use:

This antibody is intended for use to qualitatively

identify PAX5 antigen by light microscopy in formalin fixed, paraffin embedded tissue sections using immunohistochemical detection methodology. Interpretation of any positive or negative staining must be complemented with the evaluation of proper controls and must be made within the context of the patient's clinical history and other diagnostic tests. A qualified pathologist must perform evaluation of the test.

## **Summary and Explanation:**

PAX5 is a B-cell lineage specific activator protein (BSAP) that is essential for maintaining the identity and function of mature B cells during late B lymphopoiesis. It also plays a role in neural development and spermatogenesis.

PAX5 is expressed in pro-, pre-, and mature B cells, and it is expressed in the vast majority of B-cell malignancies. Anti-PAX5 is a specific marker for the B cell lineage. A study of PAX5 immunohistochemistry by Jensen et al. suggested that PAX5 may be the only detectable marker of B lineage cells in lymphomas that lack or show equivocal CD45RB and CD20 expression. PAX5 is thus useful for a panel of antibodies for the identification of cellular origin of undifferentiated tumors. The expression of PAX5 in endocrine tumors has been shown to be high in Merkel cell carcinoma and small cell carcinoma, but not carcinoid tumor. PAX5 is also a marker for nueronendocrine carcinomas.

Immunogen: A synthetic peptide corresponding to residues of human PAX5 protein.

**Isotype:** Rabbit IgG.

## **Reagent Provided:**

Concentrated format: Antibody to PAX5 is diluted in antibody diluent, with 1% bovine serum

albumin (BSA) and 0.05% sodium azide (NaN3).

Recommended dilutions: 1:50 - 1:100.

The antibody dilution and protocol may vary depending on the specimen preparation and specific application. Optimal conditions should be

determined by individual laboratory.

**Pre-diluted format:** PathnSitu ready to use antibodies are pre tittered to optimal staining

conditions. Further dilution may loose the activity and may yield to sub

optimal staining.

Storage Recommendations: Store at 2°-8°C. Do not use after expiration date provided on the vial.

**Staining Recommendations:** 

Antigen Retrieval Solution: Use CitrateBuffer(PathnSitu Cat # PS007) as antigen retrieval solution

Heat Retrieval Method: Retrieve sections under steam pressure for 15 min using PathnSitu's MERS (Multi Epitope Retrieval System) then allow solution to cool for 10 minutes then transfer tissue sections/slides to

distilled water.

**Primary Antibody:** Cover the tissue sections with primary antibody and incubate for 30

min at room temperature when used PathnSitu PolyExcel Detection

System.

**Detection System:** Refer to PathnSitu PolyExcel detection system protocol or manufacturer's

detection kit staining protocol when used other vendor detection system.

**Cellular Localization:** Nuclear.

**Positive Control:** Tonsil, B-Lymphoblastic Neoplasms.

**Troubleshooting:** Follow the antibody specific protocol recommendations according to data sheet

provided. If unusual results occur, contact PathnSitu Technical Support at 040-

2701 5544 or techsupport@pathnsitu.com.

**Limitations and Warranty:** There are no warranties, expressed or implied, which extend beyond this

description. PathnSitu is not liable for property damage, personal injury, or

economic loss caused by this product.

**Bibliography:** 1.Adams B, et al.: Genes Dev1992, 6:1589-1607

Fuxa M, et al.: CurrOpinImmunol2007, 19:129-136
Jensen KC, et al.: Mod Pathol2007, 20:871-877
Dong HY, et al.: Am J SurgPathol2005, 29:687-692
Torlakovic E, et al.: Am J ClinPathol2006, 126:798-804
Mhawech-Fauceglia P, et al.: J ClinPathol2007, 60:709-714

7. Sica G, et al.: Am J ClinPathol2008, 129:556-562

PAX5, EP156 antibody has been created by Epitomics Inc., using Epitomics' proprietary rabbit monoclonal antibody technology covered under Patent No.'s 5,675,063 and 7,402,409.